o6-benzylguanine
Central Nervous System Neoplasm
Explore 48 assets in Central Nervous System Neoplasm →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00436436CT.gov O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy | — | Terminated | — | — | — |
NCT00253487CT.gov Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas | — | Completed | — | — | — |
NCT00006474CT.gov Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma | — | Completed | — | — | — |
NCT00005081CT.gov Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma | — | Completed | — | — | — |
NCT00020150CT.gov Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors | — | Completed | — | — | — |
NCT00004892CT.gov O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma | — | Completed | — | — | — |
NCT00003567CT.gov Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | — | Terminated | — | — | — |
NCT00003348CT.gov Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain | — | Completed | — | — | — |
NCT00002971CT.gov O(6)-Benzylguanine in Treating Patients With Malignant Glioma | — | Completed | — | — | — |
NCT00046878CT.gov Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Central Nervous System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| o6-benzylguanine (this asset) | National Cancer Institute (NCI) | P2 | B · 60 |
| Procarbazine | Universitätsmedizin Mannheim | P3 | BBB |
| Vincristine Sulfate | Northwestern University | P3 | BBB |
| Irinotecan | EpicentRx, Inc. | P2 | BBB |
| Etoposide | NewLink Genetics Corporation | P3 | BBB |
| Gefitinib | Memorial Sloan Kettering Cancer Center | P2 | BBB |
| Isocyclophosphamide | Masonic Cancer Center, University of Minnesota | P3 | BBB |
| Camustine | Lisata Therapeutics, Inc. | P3 | BBB |
| Carboplatin | OHSU Knight Cancer Institute | P3 | BBB |
+42 more in the Central Nervous System Neoplasm cohort
Other indications for o6-benzylguanine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Central Nervous System Cancer | — | P3 | B · 60 |
| Gliosarcoma | — | P2 | B · 59 |
| Brain Neoplasm | — | P2 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. o6-benzylguanine in Central Nervous System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/o6-benzylguanine-central-nervous-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →